Alexion Pharmaceuticals Inc (ALXN): John B Moriarty , EVP & General Counsel of Alexion Pharmaceuticals Inc sold 918 shares on Jun 13, 2016. The Insider selling transaction was reported by the company on Jun 14, 2016 to the Securities and Exchange Commission. The shares were sold at $135.72 per share for a total value of $124,590.96 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 18, 2016, Martin Mackay (EVP & Global Head of R&D) sold 4,097 shares at $139.81 per share price.On May 13, 2016, Heidi L Wagner (SVP, Global Government Affairs) sold 53 shares at $138.65 per share price.Also, On Apr 5, 2016, David Hallal (CEO) sold 1,414 shares at $136.04 per share price.On Mar 4, 2016, Julie O’neill (EVP. Global Operations) sold 651 shares at $149.55 per share price.
Shares of Alexion Pharmaceuticals (ALXN) ended Friday, Jun 10, 2016 session in red amid volatile trading. The shares closed down -2.63 points or -1.90% at $135.61 with 19,83,755 shares getting traded. Post opening the session at $136.7, the shares hit an intraday low of $134.02 and an intraday high of $137.86 and the price vacillated in this range throughout the day. The company has a market cap of $30,379 M and the number of outstanding shares has been calculated to be 22,40,20,160 shares. The 52-week high of Alexion Pharmaceuticals is $208.88 and the 52-week low is $124.16.
Company has been under the radar of several Street Analysts.Alexion Pharmaceuticals is Reiterated by Barclays to Equal Weight and the brokerage firm has raised the Price Target to $ 180 from a previous price target of $175 .The Rating was issued on May 9, 2016.
Alexion Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23 2015 the Company had eight product candidates in clinical trials for 11 indications. The Company’s product pipeline includes complement inhibitor portfolio metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris ALXN1007 ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq Kanuma ALXN1101 and SBC-103. The Company’s preclinical candidates include mRNA Therapies SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) two life-threatening ultra-rare disorders.